**Lidocaine (systemic)**

**Class:** Antiarrhythmic Agent, Class Ib; Local Anesthetic

**Indications:** Local and regional anesthesia by infiltration, nerve block, epidural, or spinal techniques; acute treatment of ventricular arrhythmias from myocardial infarction or cardiac manipulation (eg, cardiac surgery)

**Note:** The routine prophylactic use of lidocaine to prevent arrhythmia associated with fibrinolytic administration or to suppress isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, and nonsustained VT is not recommended (Antman, 2004).

Unlabeled: ACLS guidelines: Hemodynamically stable monomorphic ventricular tachycardia (VT) (preserved ventricular function); polymorphic VT (preserved ventricular function); drug-induced monomorphic VT; when amiodarone is not available, pulseless VT or ventricular fibrillation (VF) (unresponsive to defibrillation, CPR, and vasopressor administration)

PALS guidelines: When amiodarone is not available, pulseless VT or VF (unresponsive to defibrillation, CPR, and epinephrine administration); consider in patients with cocaine overdose to prevent arrhythmias secondary to MI

I.V. infusion for chronic pain syndrome

**Available dosage form in the hospital:** LIDOCAINE 1% + ADRENALINE 50ML VIAL
LIDOCAINE 1%, PLAIN 50 ML VIAL
LIDOCAINE 2% (40MG/2ML) AMP
LIDOCAINE 2% + 1:8000 ADRENALINE CARTRIDGES (1.8/2ML)
LIDOCAINE 2% + ADRENALINE 50ML VIAL
LIDOCAINE 3% + ADRENALINE 50ML VIAL
LIDOCAINE 3% CARTRIDGE INJ
LIDOCAINE 2%, PLAIN 50ML VIAL
LIDOCAINE HCL 2%, 10 ML AMP
LIDOCAINE2%+ADRENALINE 20ML VIAL

**Trade Names:**

**Dosage:** Antiarrhythmic (ACLS, 2010):

VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration) if amiodarone is not available: I.V., intraosseous (I.O.): Initial: 1-1.5 mg/kg. If refractory VF or pulseless VT, repeat 0.5-0.75 mg/kg bolus every 5-10 minutes (maximum cumulative dose: 3 mg/kg). Follow with continuous infusion (1-4 mg/minute) after return of perfusion. Reappearance of arrhythmia
during constant infusion: 0.5 mg/kg bolus and reassessment of infusion (Zipes, 2000)

**Endotracheal (loading dose only):** 2-3.75 mg/kg (2-2.5 times the recommended I.V. dose); dilute in 5-10 mL NS or sterile water. **Note:** Absorption is greater with sterile water and results in less impairment of \( \text{PaO}_2 \).

**Hemodynamically stable monomorphic VT:** I.V.: 1-1.5 mg/kg; repeat with 0.5-0.75 mg/kg every 5-10 minutes as necessary (maximum cumulative dose: 3 mg/kg). Follow with continuous infusion of 1-4 mg/minute (or 14-57 mcg/kg/minute).

**Note:** Reduce maintenance infusion in patients with CHF, shock, or hepatic disease; initiate infusion at 10 mcg/minute (maximum dose: 1.5 mg/minute or 20 mcg/kg/minute).

**Renal impairment:** No dosage adjustment provided in manufacturer’s labeling. However, accumulation of metabolites may be increased in renal dysfunction. Not dialyzable (0% to 5%) by hemo- or peritoneal dialysis; supplemental dose is not necessary.

**Hepatic impairment:** Use with caution; reduce maintenance infusion. Initial: 0.75 mg/minute or 10 mcg/kg/minute; maximum dose: 1.5 mg/minute or 20 mcg/kg/minute. Monitor lidocaine concentrations closely and adjust infusion rate as necessary; consider alternative therapy.

**Common side effects:** Effects vary with route of administration. Many effects are dose related.

Frequency not defined.

- **Cardiovascular:** Arrhythmia, bradycardia, arterial spasms, cardiovascular collapse, defibrillator threshold increased, edema, flushing, heart block, hypotension, sinus node supression, vascular insufficiency (periarticular injections)

- **Central nervous system:** Agitation, anxiety, apprehension, coma, confusion, disorientation, dizziness, drowsiness, euphoria, hallucinations, headache, hyperesthesia, hypoesthesia, lethargy, lightheadedness, nervousness, psychosis, seizure, slurred speech, somnolence, unconsciousness

- **Gastrointestinal:** Metallic taste, nausea, vomiting

- **Local:** Thrombophlebitis

- **Neuromuscular & skeletal:** Paresthesia, transient radicular pain (subarachnoid administration; up to 1.9%), tremor, twitching, weakness

- **Otic:** Tinnitus

- **Respiratory:** Bronchospasm, dyspnea, respiratory depression or arrest

- **Miscellaneous:** Allergic reactions, anaphylactic reaction, anaphylactoid reaction, sensitivity to temperature extremes
Following spinal anesthesia: Positional headache (3%), shivering (2%), double vision (<1%), cauda equina syndrome, hypotension, nausea, peripheral nerve symptoms, respiratory inadequacy

Postmarketing and/or case reports: Asystole, disorientation, methemoglobinemia, skin reaction

Pregnancy Risk Factor: B